At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Pre-Mkt 01-21 04:06:08 EST
331.00
+0.59
+0.18%
High331.34Low321.71Vol2.95M
Open325.58D1 Closing330.41Amplitude2.91%
Mkt Cap178.24BTradable Cap177.75BTotal Shares538.48M
T/O971.40MT/O Rate0.55%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Bernstein downgrades Amgen (AMGN) to a Hold
TIPRANKS  ·  08:07
Bernstein downgrades Amgen (AMGN) to a Hold
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Qiagen (QGEN)
TIPRANKS  ·  08:00
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Qiagen (QGEN)
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Reuters  ·  01:08
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Nonprofit Sues Amgen Over Termination of Discounted Drug Sales
Reuters  ·  00:34
Nonprofit Sues Amgen Over Termination of Discounted Drug Sales
Amgen Cut to Market Perform From Outperform by Bernstein
Dow Jones  ·  00:22
Amgen Cut to Market Perform From Outperform by Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
TIPRANKS  ·  01-20 23:20
Amgen downgraded to Market Perform from Outperform at Bernstein
Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing -- Barrons.com
Dow Jones  ·  01-16
Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing -- Barrons.com
Amgen Expands Sleep Apnea Pipeline With Phase 3 Trial of Maridebart Cafraglutide
TIPRANKS  ·  01-16
Amgen Expands Sleep Apnea Pipeline With Phase 3 Trial of Maridebart Cafraglutide
Amgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next
TIPRANKS  ·  01-16
Amgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next
FACTBOX-Major deals involving U.S. drugmakers and biotechs over the past decade
Reuters  ·  01-15
FACTBOX-Major deals involving U.S. drugmakers and biotechs over the past decade
CytomX Therapeutics unveils advances in masked oncology therapeutics and pipeline progress
Reuters  ·  01-15
CytomX Therapeutics unveils advances in masked oncology therapeutics and pipeline progress
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Benzinga_recent_news  ·  01-15
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Weight-Loss Drugs Enter Era of "Long-Term Maintenance + Low-Frequency Injections"; Amgen's (AMGN.US) "Monthly" Advantage Leads $100 Billion Market
Stock News  ·  01-14
Weight-Loss Drugs Enter Era of "Long-Term Maintenance + Low-Frequency Injections"; Amgen's (AMGN.US) "Monthly" Advantage Leads $100 Billion Market
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman
Benzinga_recent_news  ·  01-14
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
Reuters  ·  01-13
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
ADVISORY-Alert incorrectly tagged to Rubicon Organics withdrawn
Reuters  ·  01-13
ADVISORY-Alert incorrectly tagged to Rubicon Organics withdrawn
BRIEF-RO: ANNOUNCES RESEARCH COLLABORATION WITH AMGEN TO EVALUATE REAL-WORLD GLP-1 COVERAGE
Reuters  ·  01-13
BRIEF-RO: ANNOUNCES RESEARCH COLLABORATION WITH AMGEN TO EVALUATE REAL-WORLD GLP-1 COVERAGE
Ro: Announces Research Collaboration With Amgen to Evaluate Real-World Glp-1 Coverage
THOMSON REUTERS  ·  01-13
Ro: Announces Research Collaboration With Amgen to Evaluate Real-World Glp-1 Coverage
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Reuters  ·  01-13
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Scotiabank Keeps Their Buy Rating on Amgen (AMGN)
TIPRANKS  ·  01-13
Scotiabank Keeps Their Buy Rating on Amgen (AMGN)

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--